GlassScriptPhysician profile
Mehnaz A Junagadhwalla
NPI 1154512705
$12,290.14
in general payments reported to CMS, 2019-2025
66 companies · $3,055 in 2025
The $3,055 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $269 · 2021: $681 · 2022: $2,174 · 2023: $2,426 · 2024: $2,406 · 2025: $3,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,565 · Education: $197 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,565.25 |
| Education | $197.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $836.33 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $820.76 | 2019-2025 | |
| Celgene Corporation | $815.76 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $776.23 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $747.93 | 2019-2025 | Opdivo, Opdualag |
| Incyte Corporation | $531.83 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $528.76 | 2022-2025 | Enhertu |
| Gilead Sciences, INC. | $424.37 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $395.89 | 2019-2025 | Venclexta, Rozlytrek, Polivy |
| Astellas Pharma US INC | $393.23 | 2019-2025 | Xtandi, Xospata, Padcev |
| Beigene USA, INC. | $383.25 | 2021-2024 | Brukinsa |
| Lilly USA, LLC | $362.14 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Janssen Biotech, INC. | $291.91 | 2019-2025 | Imbruvica, Darzalex, Rybrevant |
| Regeneron Healthcare Solutions, INC. | $290.37 | 2019-2025 | Libtayo |
| Genzyme Corporation | $262.49 | 2019-2025 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $256.31 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $254.00 | 2020-2025 | |
| Glaxosmithkline, LLC. | $227.37 | 2023-2025 | Ojjaara, Shingrix |
| Jazz Pharmaceuticals INC. | $197.28 | 2021-2025 | |
| Beone Medicines USA, INC. | $189.98 | 2025 | Brukinsa, Tevimbra |
| Amgen INC. | $189.24 | 2019-2023 | Lumakras, Xgeva, Vectibix |
| Abbvie INC. | $182.23 | 2019-2025 | |
| Adc Therapeutics America, INC. | $168.53 | 2022-2025 | |
| Array Biopharma INC | $154.99 | 2019-2025 | Lorbrena, Braftovi, Mektovi |
| Astrazeneca Pharmaceuticals LP | $153.63 | 2019-2025 | Imfinzi, Calquence |
| Exelixis INC. | $143.79 | 2019-2025 | Cabometyx |
| Sumitomo Pharma America, INC. | $130.36 | 2023-2025 | Orgovyx |
| Acrotech Biopharma INC. | $125.00 | 2024 | Beleodaq |
| Takeda Pharmaceuticals U.S.A., INC. | $124.22 | 2022-2025 | Fruzaqla, Ninlaro |
| Genmab U.S., INC. | $121.84 | 2025 | Epkinly |
| Kite Pharma, INC. | $115.33 | 2020-2023 | Yescarta |
| Pharmaessentia USA Corporation | $109.90 | 2023-2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $108.05 | 2021-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $102.37 | 2023 | Tazverik |
| Pharmacyclics LLC, An Abbvie Company | $98.43 | 2022-2023 | Imbruvica |
| Puma Biotechnology, INC. | $96.72 | 2019-2025 | |
| Eisai INC. | $88.17 | 2023-2025 | |
| Stemline Therapeutics INC. | $84.50 | 2023-2025 | Orserdu |
| Mirati Therapeutics, INC. | $80.84 | 2023-2024 | Krazati |
| Emd Serono, INC. | $74.31 | 2019-2024 | Bavencio |
| Recordati_rare_diseases_inc. | $69.43 | 2023-2025 | Sylvant, Enjaymo |
| Karyopharm Therapeutics INC. | $60.94 | 2022-2025 | Xpovio |
| Legend Biotech USA INC. | $59.33 | 2024-2025 | Carvykti |
| Taiho Oncology, INC. | $51.43 | 2023-2024 | |
| Blueprint Medicines Corporation | $50.58 | 2023-2025 | Ayvakit |
| Genentech, INC. | $49.95 | 2021 | |
| Sobi, INC | $46.02 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $42.50 | 2020-2024 | Rezlidhia, Tavalisse |
| Deciphera Pharmaceuticals INC. | $41.57 | 2021-2023 | Qinlock |
| Dendreon Pharmaceuticals LLC | $39.91 | 2022 | |
| Springworks Therapeutics, INC. | $31.66 | 2025 | Ogsiveo |
| Clovis Oncology, INC. | $28.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.68 | 2025 | |
| Alexion Pharmaceuticals, INC. | $26.01 | 2025 | Ultomiris |
| Servier Pharmaceuticals LLC | $24.98 | 2024 | |
| Iovance Biotherapeutics, INC. | $22.77 | 2025 | Amtagvi |
| Alnylam Pharmaceuticals INC. | $22.42 | 2019 | |
| Heron Therapeutics, INC. | $19.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.87 | 2022 | |
| G1 Therapeutics, INC. | $19.29 | 2022 | |
| Ge Healthcare | $18.51 | 2022 | |
| Agios Pharmaceuticals, INC. | $18.25 | 2024 | Pyrukynd |
| Dova Pharmaceuticals | $17.05 | 2021 | |
| Cti Biopharma Corp. | $15.25 | 2023 | Vonjo |
| Myovant Sciences INC. | $13.97 | 2022 | |
| Myriad Genetic Laboratories, INC. | $13.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehnaz Junagadhwalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.